Journal of Hematology Oncology Pharmacy

Click Here to

Breaking

News, Updates,

& More

Stay Up

to Date

Featured Articles

Welcome to the First Annual Issue of HOPA Abstracts, 2021

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts

Welcome to the special issue of the Journal of Hematology Oncology Pharmacy (JHOP), the official publisher of the Hematology Oncology Pharmacy Association (HOPA). This special issue represents the First Annual Issue of HOPA Abstracts, 2021, and features a selection of the abstracts presented at the 17th Annual Conference of HOPA.

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts

Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts

Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts

Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts

Most Popular Articles

Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan

Ekim Ekinci, PharmD, MS, BCOP, James E. Cox, PharmD, BCOP, Joe E. Ensor, PhD, Edward McLean, PharmD, BCOP, Carlos A. Ramos, MD, Premal D. Lulla, MD, Rammurti T. Kamble, MD, George Carrum, MD

JHOP - February 2021 Vol 11, No 1 - Original Research

Evaluation of Infusion-Related and Hypersensitivity Reactions to Chemotherapy Over a Decade at a Community Cancer Center

Sarah M. Hayes, PharmD, BCOP, Jeremy Whalen, PharmD, BCOP, Nick Schutz, PharmD, Joseph Levine, MD

JHOP - February 2021 Vol 11, No 1 - Original Research

Optimizing Response to Enasidenib with Dose Escalation in Relapsed or Refractory Acute Myeloid Leukemia

Amany R. Keruakous, MD, Sarah A. Schmidt, PharmD, Marcus T. Autry, PharmD, Julia Ye, PharmD Candidate, Phoi Nguyen, PharmD Candidate, Silas Day

JHOP - February 2021 Vol 11, No 1 - Case Reports

Optimizing Daratumumab Infusion: Assessing the Safety and Feasibility of Omitting Preinfusion Medications and Decreasing Infusion Time

Justine Preedit, PharmD, Anya Yudchyts, PharmD, BCOP

JHOP - February 2021 Vol 11, No 1 - Retrospective Analysis

Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy

Robert J. Ignoffo, PharmD, FASHP, FCSHP